Resting-state fMRI studies of postpartum depression have produced inconsistent results for years. A 2026 voxel-based meta-analysis pooled 12 studies of 475 patients and found 4 reliable regional differences (amygdala, precuneus, occipital, precentral cortex) at uncorrected thresholds, none of which held up under strict family-wise error correction.1 Research Highlights 12-study fMRI pool: Chen et al. analyzed …
Zuranolone, a novel antidepressant, shows promise in treating depression, as evidenced by a recent meta-analysis. A new study investigated zuranolone’s efficacy and safety, focusing on short-term rapid antidepressant effects. Highlights: Zuranolone Effectiveness: Demonstrated significant improvement in depression severity scores compared to placebo, with notable effects by day 15. Treatment-Emergent Adverse Events (TEAEs): Increased incidence in …
Allopregnanolone agonists represent a promising new class of medications for treating depressive disorders. Evidence suggests that allopregnanolone agonists exhibit rapid-onset of antidepressant action – particularly in women with postpartum depression (PPD). Key facts: Allopregnanolone is a neurosteroid that acts as a positive allosteric modulator of GABAA receptors and is decreased in depressive disorders. The allopregnanolone …
PMS (Premenstrual Syndrome) is a condition characterized by unwanted symptoms such as mood swings, fatigue, food cravings, irritability, and depression. These symptoms tend to occur during the second half of a woman’s menstrual cycle and tend to subside approximately a couple days after the start of the menstrual period. As of now, these current symptoms …